Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

PVT1 Long Non-coding RNA in Gastrointestinal Cancer.

Martínez-Barriocanal Á, Arango D, Dopeso H.

Front Oncol. 2020 Jan 31;10:38. doi: 10.3389/fonc.2020.00038. eCollection 2020. Review.

2.

Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.

Kim SH, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F, da Silva EM, Gularte-Mérida R, Sun Z, Fujisawa S, Smith CG, Ferrando L, Martins Sebastião AP, Bykov Y, Li A, Silveira C, Ashley CW, Stylianou A, Selenica P, Samore WR, Jungbluth AA, Zamarin D, Abu-Rustum NR, Helin K, Soslow RA, Reis-Filho JS, Oliva E, Weigelt B.

Nat Commun. 2020 Jan 2;11(1):44. doi: 10.1038/s41467-019-13806-x.

3.

PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα.

Dopeso H, Jiao HK, Cuesta AM, Henze AT, Jurida L, Kracht M, Acker-Palmer A, Garvalov BK, Acker T.

Cancer Res. 2018 Apr 1;78(7):1805-1819. doi: 10.1158/0008-5472.CAN-17-1346. Epub 2018 Jan 16.

4.

Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.

Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Cartón-García F, Macaya I, de Marcondes PG, Anguita E, Masanas M, Jiménez-Flores LM, Martínez-Barriocanal Á, Nieto R, Segura MF, Schwartz S Jr, Mariadason JM, Arango D.

Br J Cancer. 2018 Jan;118(1):106-116. doi: 10.1038/bjc.2017.420. Epub 2017 Dec 5.

5.

Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.

Mateo-Lozano S, Bazzocco S, Rodrigues P, Mazzolini R, Andretta E, Dopeso H, Fernández Y, Del Llano E, Bilic J, Suárez-López L, Macaya I, Cartón-García F, Nieto R, Jimenez-Flores LM, de Marcondes PG, Nuñez Y, Afonso E, Cacci K, Hernández-Losa J, Landolfi S, Abasolo I, Ramón Y Cajal S, Mariadason JM, Schwartz S Jr, Matsui T, Arango D.

Sci Rep. 2017 Mar 6;7:43702. doi: 10.1038/srep43702.

6.

Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.

Andretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, Bazzocco S, Bilic J, Rodrigues P, Nieto R, Landolfi S, Ramon Y Cajal S, Schwartz S, Brown A, Dopeso H, Arango D.

Sci Rep. 2017 Feb 7;7:41576. doi: 10.1038/srep41576.

7.

Myo5b knockout mice as a model of microvillus inclusion disease.

Cartón-García F, Overeem AW, Nieto R, Bazzocco S, Dopeso H, Macaya I, Bilic J, Landolfi S, Hernandez-Losa J, Schwartz S Jr, Ramon y Cajal S, van Ijzendoorn SC, Arango D.

Sci Rep. 2015 Jul 23;5:12312. doi: 10.1038/srep12312.

8.

Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment.

Bazzocco S, Dopeso H, Carton-Garcia F, Macaya I, Andretta E, Chionh F, Rodrigues P, Garrido M, Alazzouzi H, Nieto R, Sanchez A, Schwartz S Jr, Bilic J, Mariadason JM, Arango D.

Clin Cancer Res. 2015 Aug 15;21(16):3695-704. doi: 10.1158/1078-0432.CCR-14-2457. Epub 2015 May 5.

9.

Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR.

Henze AT, Garvalov BK, Seidel S, Cuesta AM, Ritter M, Filatova A, Foss F, Dopeso H, Essmann CL, Maxwell PH, Reifenberger G, Carmeliet P, Acker-Palmer A, Acker T.

Nat Commun. 2014 Nov 25;5:5582. doi: 10.1038/ncomms6582.

10.

PHD3 regulates EGFR internalization and signalling in tumours.

Garvalov BK, Foss F, Henze AT, Bethani I, Gräf-Höchst S, Singh D, Filatova A, Dopeso H, Seidel S, Damm M, Acker-Palmer A, Acker T.

Nat Commun. 2014 Nov 25;5:5577. doi: 10.1038/ncomms6577.

PMID:
25420589
11.

RHOA inactivation enhances Wnt signalling and promotes colorectal cancer.

Rodrigues P, Macaya I, Bazzocco S, Mazzolini R, Andretta E, Dopeso H, Mateo-Lozano S, Bilić J, Cartón-García F, Nieto R, Suárez-López L, Afonso E, Landolfi S, Hernandez-Losa J, Kobayashi K, Ramón y Cajal S, Tabernero J, Tebbutt NC, Mariadason JM, Schwartz S Jr, Arango D.

Nat Commun. 2014 Nov 21;5:5458. doi: 10.1038/ncomms6458.

12.

Brush border myosin Ia inactivation in gastric but not endometrial tumors.

Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM, Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S, Hernandez-Losa J, Macaya I, Suzuki H, Ramón y Cajal S, Mooseker MS, Mariadason JM, Gebert J, Hofstra RM, Reventós J, Yamamoto H, Schwartz S Jr, Arango D.

Int J Cancer. 2013 Apr 15;132(8):1790-9. doi: 10.1002/ijc.27856. Epub 2012 Oct 20.

13.

Villin expression is frequently lost in poorly differentiated colon cancer.

Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM.

Am J Pathol. 2012 Apr;180(4):1509-21. doi: 10.1016/j.ajpath.2012.01.006. Epub 2012 Feb 18.

14.

Brush border myosin Ia has tumor suppressor activity in the intestine.

Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. doi: 10.1073/pnas.1108411109. Epub 2012 Jan 18.

15.

Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D.

Clin Cancer Res. 2010 Apr 15;16(8):2375-82. doi: 10.1158/1078-0432.CCR-09-3275. Epub 2010 Apr 6.

16.

An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression.

Yuan Z, Shin J, Wilson A, Goel S, Ling YH, Ahmed N, Dopeso H, Jhawer M, Nasser S, Montagna C, Fordyce K, Augenlicht LH, Aaltonen LA, Arango D, Weber TK, Mariadason JM.

Cancer Res. 2009 Oct 1;69(19):7811-8. doi: 10.1158/0008-5472.CAN-09-0986. Epub 2009 Sep 29. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275.

17.

The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.

Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernández-Losa J, Castaño J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz S Jr, Arango D.

Cancer Res. 2009 Sep 15;69(18):7430-8. doi: 10.1158/0008-5472.CAN-09-0706. Epub 2009 Sep 8.

18.

Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families.

Romero-Giménez J, Dopeso H, Blanco I, Guerra-Moreno A, Gonzalez S, Vogt S, Aretz S, Schwartz S Jr, Capella G, Arango D.

Int J Cancer. 2008 Mar 15;122(6):1422-5.

19.

EPHB4 and survival of colorectal cancer patients.

Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz S Jr, Arango D.

Cancer Res. 2006 Sep 15;66(18):8943-8.

20.

High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability.

Davalos V, Dopeso H, Velho S, Ferreira AM, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen RC, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Plaja A, Perucho M, Imai K, Yamamoto H, Gebert JF, Díaz-Chico JC, Hofstra RM, Woerner SM, Seruca R, Schwartz S Jr, Arango D.

Oncogene. 2007 Jan 11;26(2):308-11. Epub 2006 Jul 3.

PMID:
16819508

Supplemental Content

Loading ...
Support Center